Medexus Pharmaceuticals Reports Record Q2 Revenue and Net Income Amid GRAFAPEX™ Growth
Medexus Pharmaceuticals (MEDXF) reported second-quarter revenue of $29.1 million, representing a 17.8% increase year-over-year. While the top-line figure missed analyst expectations by $1.31 million, the company achieved several record milestones, including an adjusted EBITDA of $5.1 million and net income of $0.8 million, marking their highest quarterly performance since fiscal Q4 2025. The growth was driven largely by GRAFAPEX™ (treosulfan) for Injection, which generated a record product-level net revenue of $5.7 million. Looking ahead, Medexus maintains its long-term commercial outlook, projecting annual product-level net revenue from GRAFAPEX to reach between $100 million and $175 million within five years of its commercial launch.
Tickers: $MEDXF
Topics: financial results product revenue revenue miss year-over-year growth